Sutent Thyroid Cancer and Sutent Gastric Cancer

The cancer that initiates in the thyroid gland is termed as thyroid cancer. A thyroid cancer may be benign or malignant. Symptoms generally include cough, thyroid swelling, problem in swallowing, hoarseness of voice and enlargement of thyroid gland.

The question whether by using Sutent Thyroid cancer can be treated or not, is still raised in clinical trials and no positive outcome has been issued yet. However, recent studies have shown that thyroid tumors positively respond to antiangiogenic agents (agents that cause destruction of the blood vessels in the concerned site). Since, the medicine under consideration is an antiangiogenic agent (being a kinase inhibitor, it antagonizes the Vascular endothelial growth factor receptors VEGFRs), it may be used to treat the cancer. So, if you want to get your thyroid cancer treated / managed, you may have to pursue a clinical trial based on sunitinib malate. Nevertheless, a small scale study based on 43 patients on Sutent Thyroid cancer interaction has already shown that a 50 mg 4/2 schedule of the drug is effective in bettering or at least stabilizing the condition of cancer. In coming years it is expected that guidance will be issued from some drug approval body regarding the effectiveness of Sutent Thyroid cancer treatment.

As far as the question is: whether by the use of Sutent Thyroid cancer is triggered or not, we may have an answer right away. It is a well known fact that each and every individual has his / her own specific genetic makeup. So, the supposition that due to the use of Sutent Thyroid cancer may be caused doesnt hold true for every one. Nonetheless, according to a study conducted in 2012 on around 13909 patients, it was found out that the probability of developing thyroid cancer as the side effect of this drug is only 0.03%. Put in another way, this fact implies that almost 3 out of every 10000 cancer patients on sunitinib therapy are likely to be developing thyroid cancer. However, since the chances are less, this side effect is of very little concern. Another important fact based on Sutent Thyroid cancer concurrence is that the event of appearance of this side effect is largely prevalent in the patients with ages ranging between 40 and 60. It is to be mentioned here that there is no considerable difference in the probabilities of induced Sutent Thyroid cancer development between males and females.

Gastric cancer or GIST is basically a cancer of gastro intestinal tract and its symptoms include abdominal pain, trouble swallowing food and gastrointestinal hemorrhages. Sunitinib is widely used for the Gastric cancer. In fact the use of sutent for GIST (Gastrointestinal Stromal tumor) has been officially approved by the Food and Drug administration (FDA). It was in the year 2006 that in a clinical trial by Pfizer, they used sutent for GIST patients and found a considerable increase in their life spans as compared to other drugs (Gleevec is one example).